Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.75 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.75 |
| ▸ | TAS1R2 | Q8TE23 | 6/20 | 0.75 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705033 | 0.86 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL27102975 | 0.83 | TAS1R3 (0.75) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL24381880 | 0.81 | THRB (0.60) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL29620077 | 0.81 | THRB (0.60) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL16130500 | 0.79 | TAS1R3 (0.74) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL704767 | 0.78 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL13833355 | 0.78 | TAS1R3 (0.80) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL20660701 | 0.78 | MAPT (0.71) | NPC1RAB9ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5279098 | 0.78 | TAS1R3 (0.56) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL3706031 | 0.76 | RAB9A (0.81) | TAS1R3TAS1R1TAS1R2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | TAS1R3 3988/4885TAS1R1 4181/4885TAS1R2 3838/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | TAS1R3 4597/4885TAS1R1 4638/4885TAS1R2 4588/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | TAS1R3 4597/4885TAS1R1 4638/4885TAS1R2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.